{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li S"],"funding":["National Natural Science Foundation of China"],"pagination":["1883-1895"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12573374"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["74(11)"],"pubmed_abstract":["<h4>Background</h4>Current treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for hepatocellular carcinoma (HCC) due to drug resistance. Emerging therapies such as chimeric antigen receptor T (CAR-T) and macrophage-based cell therapies are promising but need to be improved.<h4>Objectives</h4>This study investigates the role of macrophage NOD-like receptor family pyrin domain containing 6 (NLRP6) in HCC progression and its therapeutic potential.<h4>Design</h4>Immunofluorescence staining was performed in patient samples. Liver tumour models (autonomous, orthotopic, subcutaneous) were developed, and RNA sequencing, flow cytometry and immunohistochemistry were performed in wild-type, <i>Nlrp6</i> <sup>-/-</sup> mice, and cell-specific Nlrp6 knocko"],"journal":["Gut"],"pubmed_title":["NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression."],"pmcid":["PMC12573374"],"funding_grant_id":["82272956"],"pubmed_authors":["Yu L","Lu Y","Fu Y","Lei G","Shi Y","Liu Z","Qian Z","Safadi R","Zhang T","Li S","Zhang X","Jia X","Han J","Zha H"],"additional_accession":[]},"is_claimable":false,"name":"NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression.","description":"<h4>Background</h4>Current treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for hepatocellular carcinoma (HCC) due to drug resistance. Emerging therapies such as chimeric antigen receptor T (CAR-T) and macrophage-based cell therapies are promising but need to be improved.<h4>Objectives</h4>This study investigates the role of macrophage NOD-like receptor family pyrin domain containing 6 (NLRP6) in HCC progression and its therapeutic potential.<h4>Design</h4>Immunofluorescence staining was performed in patient samples. Liver tumour models (autonomous, orthotopic, subcutaneous) were developed, and RNA sequencing, flow cytometry and immunohistochemistry were performed in wild-type, <i>Nlrp6</i> <sup>-/-</sup> mice, and cell-specific Nlrp6 knocko","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-05T09:43:59.459Z","creation":"2026-05-15T03:12:00.214Z"},"accession":"S-EPMC12573374","cross_references":{"pubmed":["40473401"],"doi":["10.1136/gutjnl-2024-334448"]}}